Sorafenib and hepatic arterial infusion chemotherapy: another failed combination
Mené sur 206 patients atteints d'un carcinome hépatocellulaire de stade avancé et non résécable, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout d'une chimiothérapie intra-artérielle hépatique à base de faibles doses de cisplatine et de fluorouracile au sorafénib
Hepatic arterial infusion chemotherapy has not been shown to improve survival for patients with advanced hepatocellular carcinoma in prospective trials and, for this reason, is not considered a standard of care. Masatoshi Kudo and colleagues,1 the authors of the SILIUS trial, reported in The Lancet Gastroenterology & Hepatology, are therefore to be congratulated for addressing the absence of evidence on the effectiveness of hepatic arterial infusion chemotherapy by doing a randomised trial comparing the standard of care, sorafenib, with sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy.
The Lancet Gastroenterology & Hepatology , commentaire, 2017